Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder

NCT02252536 is registered in ClinicalTrials.gov with National Institute on Alcohol Abuse and Alcoholism (NIAAA) as lead sponsor.

NCT NCT02252536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02252536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2015
Completion date
March 31, 2017
Enrollment
346 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol use disorder